Apoptosis Incidence and Protein Expression of p53, TGF-β Receptor II, p27Kip1, and Smad4 in Benign, Premalignant, and Malignant Human Prostate

Li Zeng, Randall G. Rowland, Subodh M. Lele, Natasha Kyprianou

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Deregulation of apoptosis is involved in prostate cancer development and progression. This study involved an immunohistochemical "profiling" of prostate tissue specimens from patients who underwent prostatectomy for localized prostate cancer, to identify apoptosis-specific alterations associated with premalignant precursor lesions. Prostate tissue was pathologically evaluated, and areas of benign acini, high-grade prostate intraepithelial neoplasia (HGPIN), and prostate cancer were identified. Immunohistochemical analysis was performed to determine the expression of p27Kip1, a key cell cycle regulator, transforming growth factor (TGF)-β receptor II (TβRII), a critical signaling effector of TGF-β; Smad4, a downstream intracellular effector of TGF-β signaling; p53, a key apoptosis regulator; and prostate-specific antigen (PSA), a clinical marker of prostate cancer. The apoptotic index of the same cell populations was determined using the transferase-mediated digoxigenin-tagged 16-desoxy-uridine-triphosphate nick end labeling assay. Our findings indicate a significant reduction in p27Kip1 immunoreactivity in HGPIN (P <0.0001) and prostate cancer (P <0.0001) compared with the benign tissue. A significant down-regulation was detected in TβRII expression in HGPIN and prostate cancer compared with benign prostatic hyperplasia (BPH)(P <0.001). A significant decrease was also observed in Smad4 levels in HGPIN and prostate cancer compared with BPH (P <0.001). Evaluation of the incidence of apoptosis revealed a significant decrease in the apoptotic index among the epithelial cell populations in HGPIN and a further decrease in prostate carcinoma (P <0.01). This reduced apoptotic index correlated with a significant increase in p53 immunoreactivity in the prostatic carcinoma foci. Prostate cancer cells exhibited strong nuclear staining for p53 compared with adjacent HGPIN (P <0.05) and the benign lesions of the same prostate specimens (P <0.05). A significant reduction in PSA immunostaining was detected in HGPIN and prostate carcinoma foci compared with the benign glandular epithelia (P <0.001). These results further define deregulation of TGF-β signaling effectors as a molecular basis for loss of apoptotic control contributing to the development of prostate tumors. Identification of apoptotic regulators in precursor premalignant lesions may have prognostic significance in disease progression as well as therapeutic value for targeting prostate cancer.

Original languageEnglish (US)
Pages (from-to)290-297
Number of pages8
JournalHuman Pathology
Volume35
Issue number3
DOIs
StatePublished - Mar 2004

Fingerprint

Growth Factor Receptors
Transforming Growth Factors
Prostate
Apoptosis
Prostatic Neoplasms
Incidence
Proteins
Neoplasms
Prostatic Hyperplasia
Prostate-Specific Antigen
Carcinoma
Digoxigenin
Uridine Triphosphate
Prostatectomy
Transferases
Population
Disease Progression
Cell Cycle
Down-Regulation
Epithelium

Keywords

  • Apoptosis
  • High-grade prostatic intraepithelial neoplasia
  • Prostate carcinoma
  • Prostate growth
  • Smad4
  • Transforming growth factor β signaling
  • p27
  • p53

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Apoptosis Incidence and Protein Expression of p53, TGF-β Receptor II, p27Kip1, and Smad4 in Benign, Premalignant, and Malignant Human Prostate. / Zeng, Li; Rowland, Randall G.; Lele, Subodh M.; Kyprianou, Natasha.

In: Human Pathology, Vol. 35, No. 3, 03.2004, p. 290-297.

Research output: Contribution to journalArticle

@article{9273d547a30b4a0d850db37974e3577a,
title = "Apoptosis Incidence and Protein Expression of p53, TGF-β Receptor II, p27Kip1, and Smad4 in Benign, Premalignant, and Malignant Human Prostate",
abstract = "Deregulation of apoptosis is involved in prostate cancer development and progression. This study involved an immunohistochemical {"}profiling{"} of prostate tissue specimens from patients who underwent prostatectomy for localized prostate cancer, to identify apoptosis-specific alterations associated with premalignant precursor lesions. Prostate tissue was pathologically evaluated, and areas of benign acini, high-grade prostate intraepithelial neoplasia (HGPIN), and prostate cancer were identified. Immunohistochemical analysis was performed to determine the expression of p27Kip1, a key cell cycle regulator, transforming growth factor (TGF)-β receptor II (TβRII), a critical signaling effector of TGF-β; Smad4, a downstream intracellular effector of TGF-β signaling; p53, a key apoptosis regulator; and prostate-specific antigen (PSA), a clinical marker of prostate cancer. The apoptotic index of the same cell populations was determined using the transferase-mediated digoxigenin-tagged 16-desoxy-uridine-triphosphate nick end labeling assay. Our findings indicate a significant reduction in p27Kip1 immunoreactivity in HGPIN (P <0.0001) and prostate cancer (P <0.0001) compared with the benign tissue. A significant down-regulation was detected in TβRII expression in HGPIN and prostate cancer compared with benign prostatic hyperplasia (BPH)(P <0.001). A significant decrease was also observed in Smad4 levels in HGPIN and prostate cancer compared with BPH (P <0.001). Evaluation of the incidence of apoptosis revealed a significant decrease in the apoptotic index among the epithelial cell populations in HGPIN and a further decrease in prostate carcinoma (P <0.01). This reduced apoptotic index correlated with a significant increase in p53 immunoreactivity in the prostatic carcinoma foci. Prostate cancer cells exhibited strong nuclear staining for p53 compared with adjacent HGPIN (P <0.05) and the benign lesions of the same prostate specimens (P <0.05). A significant reduction in PSA immunostaining was detected in HGPIN and prostate carcinoma foci compared with the benign glandular epithelia (P <0.001). These results further define deregulation of TGF-β signaling effectors as a molecular basis for loss of apoptotic control contributing to the development of prostate tumors. Identification of apoptotic regulators in precursor premalignant lesions may have prognostic significance in disease progression as well as therapeutic value for targeting prostate cancer.",
keywords = "Apoptosis, High-grade prostatic intraepithelial neoplasia, Prostate carcinoma, Prostate growth, Smad4, Transforming growth factor β signaling, p27, p53",
author = "Li Zeng and Rowland, {Randall G.} and Lele, {Subodh M.} and Natasha Kyprianou",
year = "2004",
month = "3",
doi = "10.1016/j.humpath.2003.11.001",
language = "English (US)",
volume = "35",
pages = "290--297",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Apoptosis Incidence and Protein Expression of p53, TGF-β Receptor II, p27Kip1, and Smad4 in Benign, Premalignant, and Malignant Human Prostate

AU - Zeng, Li

AU - Rowland, Randall G.

AU - Lele, Subodh M.

AU - Kyprianou, Natasha

PY - 2004/3

Y1 - 2004/3

N2 - Deregulation of apoptosis is involved in prostate cancer development and progression. This study involved an immunohistochemical "profiling" of prostate tissue specimens from patients who underwent prostatectomy for localized prostate cancer, to identify apoptosis-specific alterations associated with premalignant precursor lesions. Prostate tissue was pathologically evaluated, and areas of benign acini, high-grade prostate intraepithelial neoplasia (HGPIN), and prostate cancer were identified. Immunohistochemical analysis was performed to determine the expression of p27Kip1, a key cell cycle regulator, transforming growth factor (TGF)-β receptor II (TβRII), a critical signaling effector of TGF-β; Smad4, a downstream intracellular effector of TGF-β signaling; p53, a key apoptosis regulator; and prostate-specific antigen (PSA), a clinical marker of prostate cancer. The apoptotic index of the same cell populations was determined using the transferase-mediated digoxigenin-tagged 16-desoxy-uridine-triphosphate nick end labeling assay. Our findings indicate a significant reduction in p27Kip1 immunoreactivity in HGPIN (P <0.0001) and prostate cancer (P <0.0001) compared with the benign tissue. A significant down-regulation was detected in TβRII expression in HGPIN and prostate cancer compared with benign prostatic hyperplasia (BPH)(P <0.001). A significant decrease was also observed in Smad4 levels in HGPIN and prostate cancer compared with BPH (P <0.001). Evaluation of the incidence of apoptosis revealed a significant decrease in the apoptotic index among the epithelial cell populations in HGPIN and a further decrease in prostate carcinoma (P <0.01). This reduced apoptotic index correlated with a significant increase in p53 immunoreactivity in the prostatic carcinoma foci. Prostate cancer cells exhibited strong nuclear staining for p53 compared with adjacent HGPIN (P <0.05) and the benign lesions of the same prostate specimens (P <0.05). A significant reduction in PSA immunostaining was detected in HGPIN and prostate carcinoma foci compared with the benign glandular epithelia (P <0.001). These results further define deregulation of TGF-β signaling effectors as a molecular basis for loss of apoptotic control contributing to the development of prostate tumors. Identification of apoptotic regulators in precursor premalignant lesions may have prognostic significance in disease progression as well as therapeutic value for targeting prostate cancer.

AB - Deregulation of apoptosis is involved in prostate cancer development and progression. This study involved an immunohistochemical "profiling" of prostate tissue specimens from patients who underwent prostatectomy for localized prostate cancer, to identify apoptosis-specific alterations associated with premalignant precursor lesions. Prostate tissue was pathologically evaluated, and areas of benign acini, high-grade prostate intraepithelial neoplasia (HGPIN), and prostate cancer were identified. Immunohistochemical analysis was performed to determine the expression of p27Kip1, a key cell cycle regulator, transforming growth factor (TGF)-β receptor II (TβRII), a critical signaling effector of TGF-β; Smad4, a downstream intracellular effector of TGF-β signaling; p53, a key apoptosis regulator; and prostate-specific antigen (PSA), a clinical marker of prostate cancer. The apoptotic index of the same cell populations was determined using the transferase-mediated digoxigenin-tagged 16-desoxy-uridine-triphosphate nick end labeling assay. Our findings indicate a significant reduction in p27Kip1 immunoreactivity in HGPIN (P <0.0001) and prostate cancer (P <0.0001) compared with the benign tissue. A significant down-regulation was detected in TβRII expression in HGPIN and prostate cancer compared with benign prostatic hyperplasia (BPH)(P <0.001). A significant decrease was also observed in Smad4 levels in HGPIN and prostate cancer compared with BPH (P <0.001). Evaluation of the incidence of apoptosis revealed a significant decrease in the apoptotic index among the epithelial cell populations in HGPIN and a further decrease in prostate carcinoma (P <0.01). This reduced apoptotic index correlated with a significant increase in p53 immunoreactivity in the prostatic carcinoma foci. Prostate cancer cells exhibited strong nuclear staining for p53 compared with adjacent HGPIN (P <0.05) and the benign lesions of the same prostate specimens (P <0.05). A significant reduction in PSA immunostaining was detected in HGPIN and prostate carcinoma foci compared with the benign glandular epithelia (P <0.001). These results further define deregulation of TGF-β signaling effectors as a molecular basis for loss of apoptotic control contributing to the development of prostate tumors. Identification of apoptotic regulators in precursor premalignant lesions may have prognostic significance in disease progression as well as therapeutic value for targeting prostate cancer.

KW - Apoptosis

KW - High-grade prostatic intraepithelial neoplasia

KW - Prostate carcinoma

KW - Prostate growth

KW - Smad4

KW - Transforming growth factor β signaling

KW - p27

KW - p53

UR - http://www.scopus.com/inward/record.url?scp=1542720308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542720308&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2003.11.001

DO - 10.1016/j.humpath.2003.11.001

M3 - Article

C2 - 15017584

AN - SCOPUS:1542720308

VL - 35

SP - 290

EP - 297

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 3

ER -